去年，Ypsomed 签署了一项长期协议，为诺和诺德提供旨在为多种代谢疾病提供自我给药治疗的自动注射器。Novo Nordisk said it has signed a contract with Ypsomed to produce the next generation of weight loss pills.
Zhitong Finance learned that people familiar with the matter revealed that Novo Nordisk (NVO.US) has signed a contract with Swiss medical device manufacturer Ypsomed, and Ypsomed will supply injection pens for Novo Nordisk's next-generation obesity treatment drug Cagrisema. The report shows the company's long-term business plan for weekly injections. It is currently in late clinical development and is expected to produce phase 3 data this year.
Cagrisema was designed to combine semaglutide with amylin, another compound that mimics metabolic hormone. Semaglutide is the active ingredient in Novo Nordisk's popular weight loss treatment WegoVy. Novo Nordisk hopes to achieve an average weight loss effect of 25% within a year. In contrast, Zepbound, a weight loss therapy developed by its competitor LLY.US (LLY.US), achieved an average weight loss of 15% and 20%, respectively, within a year.
Last year, Ypsomed signed a long-term agreement to supply Novo Nordisk with autoinjectors designed to provide self-administered treatments for a variety of metabolic diseases.
